The evolving role of radiotherapy in treatment of oligometastatic NSCLC

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2010;(5):CD007309.
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Jeppesen SS, Schytte T, Jensen HR, et al. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates. Acta Oncol. 2013;52(7):1552–1558.
   PubMed Web of Science ®Google Scholar
• Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–637.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076.
   PubMed Web of Science ®Google Scholar
• Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618–1626.
   PubMed Web of Science ®Google Scholar
• Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–355.
   PubMed Web of Science ®Google Scholar
• Jabbour SK. Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities? J Clin Oncol. 2014;32(34):3794–3796.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–458.
   PubMed Web of Science ®Google Scholar
• Rubin P. Comment: are metastases curable? JAMA. 1968;204(7):612–613.
   PubMed Web of Science ®Google Scholar
• Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999;35(14):1963–1973.
   PubMed Web of Science ®Google Scholar
• Hellman S. Evolving paradigms and perceptions of cancer. Nat Clin Pract Oncol. 2005;2(12):618–624.
   PubMedGoogle Scholar
• Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.
   PubMedGoogle Scholar
• Predina JD, Puc MM, Bergey MR, et al. Improved survival after pulmonary metastasectomy for soft tissue sarcoma. J Thorac Oncol. 2011;6(5):913–919.
   PubMed Web of Science ®Google Scholar
• Qiu H, Katz AW, Chowdhry AK, et al. Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol. 2015. [Epub ahead of print]
   Google Scholar
• Salama JK, Chmura SJ. The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol. 2014;41(6):790–797.
   PubMed Web of Science ®Google Scholar
• Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol. 2014;20(15):4220–4229.
   PubMed Web of Science ®Google Scholar
• Patel PR, Yoo DS, Niibe Y, et al. A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulm Med. 2012;2012:480961.
   PubMedGoogle Scholar
• Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–1814.
   PubMed Web of Science ®Google Scholar
• Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32(34):3824–3830.
   PubMed Web of Science ®Google Scholar
• Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012;75(1):9–14.
   PubMed Web of Science ®Google Scholar
• Parikh RB, Cronin AM, Kozono DE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;89(4):880–887.
   PubMed Web of Science ®Google Scholar
• Mehta N, Mauer AM, Hellman S, et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004;25(6):1677–1683.
   PubMed Web of Science ®Google Scholar
• Yano T, Okamoto T, Haro A, et al. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer. 2013;82(3):431–435.
   PubMed Web of Science ®Google Scholar
• Torok J, Kelsey CR, Salama JK. Patterns of distant metastases in surgically managed early stage non-small cell lung cancer. 2013: Paper presentation, 55th Annual ASTRO Meeting. 2013 Sept; Atlanta, GA.
   Google Scholar
• Li J, Xu W, Kong F, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22(3):151–155.
   PubMed Web of Science ®Google Scholar
• Weber WA, Dietlein M, Hellwig D, et al. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer]. Nuklearmedizin. 2003;42(4):135–144.
   PubMedGoogle Scholar
• Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol. 2012;30(22):2725–2730.
   PubMed Web of Science ®Google Scholar
• De Pas TM, de Braud F, Catalano G, et al. Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Ann Thorac Surg. 2007;83(1):231–234.
   PubMed Web of Science ®Google Scholar
• Oh Y, Taylor S, Bekele BN, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115(13):2930–2938.
   PubMed Web of Science ®Google Scholar
• Cheruvu P, Metcalfe SK, Metcalfe J, et al. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol. 2011;6:80.
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Hammerman SF, Kavanagh BD, et al. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48(4):578–583.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857–865.
   PubMed Web of Science ®Google Scholar
• Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer. 2010;69(3):251–258.
   PubMed Web of Science ®Google Scholar
• Collaud S, Stahel R, Inci I, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer. 2012;78(3):234–238.
   PubMed Web of Science ®Google Scholar
• Congedo MT, Cesario A, Lococo F, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. J Thorac Cardiovasc Surg. 2012;144(2):444–452.
   PubMed Web of Science ®Google Scholar
• Di Lascio S, Pagani O. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel). 2014;9(1):7–14.
   PubMed Web of Science ®Google Scholar
• American College of Radiology (ACR). Practice guideline for the performance of stereotactic body radiation therapy. Reston (VA): ACR; 2009. p. 8.
   Google Scholar
• Loo BW Jr., Chang JY, Dawson LA, et al. Stereotactic ablative radiotherapy: what’s in a name? Pract Radiat Oncol. 2011;1(1):38–39.
   Google Scholar
• Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82(6):1062–1070.
   PubMed Web of Science ®Google Scholar
• Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006;81(2):163–167.
   PubMed Web of Science ®Google Scholar
• Yano T, Haro A, Yoshida T, et al. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol. 2010;102(7):852–855.
   PubMed Web of Science ®Google Scholar
• Jabbour SK, Daroui P, Moore D, et al. A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis. 2011;3(1):4–9.
   Google Scholar
• De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012;7(10):1547–1555.
   PubMed Web of Science ®Google Scholar
• Hasselle MD, Haraf DJ, Rusthoven KE, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(2):376–381.
   PubMed Web of Science ®Google Scholar
• Griffioen GH, Toguri D, Dahele M, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer. 2013;82(1):95–102.
   PubMed Web of Science ®Google Scholar
• Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014;25(10):1954–1959.
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–886.
   PubMed Web of Science ®Google Scholar
• McCammon R, Schefter TE, Gaspar LE, et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73(1):112–118.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Villarreal-Garza C, Zamora J, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011;6:166.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425.
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol. 1999;44(3):275–281.
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Shanley R, Luo X, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys. 2014;90(3):526–531.
   PubMed Web of Science ®Google Scholar
• Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–1672.
   PubMed Web of Science ®Google Scholar
• McTyre E, Scott J, Chinnaiyan P. Whole brain radiotherapy for brain metastasis. Surg Neurol Int. 2013;4(Suppl 4): S236–44.
   PubMedGoogle Scholar
• Hahn C, Kavanagh B, Bhatnagar A, et al. Choosing wisely: the American Society for Radiation Oncology’s top 5 list. Pract Radiat Oncol. 2014;4(6):349–355.
   Google Scholar
• Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91(4):710–717.
   PubMed Web of Science ®Google Scholar
• Aoyama H, Tago M, Shirato H, et al. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015;1(4):457–464.
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–1584.
   PubMed Web of Science ®Google Scholar
• Navarria P, Ascolese A, Tomatis S, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9(1):91.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys. 2015;91(2):337–343.
   PubMed Web of Science ®Google Scholar
• Patel PR, Milano MT, Onaitis MW, et al. Treatment considerations for synchronous primary NSCLC and oligometastatic disease. In: Bogart J. DF, editor. Treatment of high-risk early stage lung cancer. New York (NY): Springer-Verlag; 2015.
   Google Scholar
• Carr LL, Finigan JH, Kern JA. Evaluation and treatment of patients with non-small cell lung cancer. Med Clin North Am. 2011;95(6):1041–1054.
   PubMed Web of Science ®Google Scholar
• Soffen EM, Solin LJ, Rubenstein JH, et al. Palliative radiotherapy for symptomatic adrenal metastases. Cancer. 1990;65(6):1318–1320.
   PubMed Web of Science ®Google Scholar
• Bastian S, Clerici T, Neuweiler J, et al. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. Onkologie. 2011;34(12):665–670.
   PubMed Web of Science ®Google Scholar
• Ippolito E, D’Angelillo RM, Fiore M, et al. SBRT: a viable option for treating adrenal gland metastases. Rep Pract Oncol Radiother. Forthcoming 2015.
   Google Scholar
• Oshiro Y, Takeda Y, Hirano S, et al. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol. 2011;34(3):249–253.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Barney BM, Macdonald OK, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013;36(5):509–513.
   PubMed Web of Science ®Google Scholar
• Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3): S94–100.
   PubMed Web of Science ®Google Scholar
• Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187(4):245–251.
   PubMed Web of Science ®Google Scholar
• Chong S, Lee KS, Kim HY, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics. 2006;26(6):1811–1824. discussion 1824-6.
   PubMed Web of Science ®Google Scholar
• Kagohashi K, Satoh H, Ishikawa H, et al. Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol. 2003;20(1):25–28.
   PubMed Web of Science ®Google Scholar
• Di Carlo I, Grasso G, Patane D, et al. Liver metastases from lung cancer: is surgical resection justified? Ann Thorac Surg. 2003;76(1):291–293.
   PubMed Web of Science ®Google Scholar
• Hoyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012;82(3):1047–1057.
   PubMed Web of Science ®Google Scholar
• Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67(3):793–798.
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–1578.
   PubMed Web of Science ®Google Scholar
• Agarwala AK, Hanna NH. Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer. 2005;6(6):367–368.
   PubMedGoogle Scholar
• Ambrogi V, Nofroni I, Tonini G, et al. Skin metastases in lung cancer: analysis of a 10-year experience. Oncol Rep. 2001;8(1):57–61.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Mantel F, Gerszten PC, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol. 2014;9:226.
   PubMed Web of Science ®Google Scholar
• Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012;13(4):395–402.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–1076.
   PubMed Web of Science ®Google Scholar
• Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34(4):797–807.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–838.
   PubMed Web of Science ®Google Scholar
• Gray PJ, Mak RH, Yeap BY, et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014;85(2):239–244.
   PubMed Web of Science ®Google Scholar
• Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012;84(1):e61–7.
   PubMed Web of Science ®Google Scholar
• Sheu T, Heymach JV, Swisher SG, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys. 2014;90(4):850–857.
   PubMed Web of Science ®Google Scholar
• Li T, Liu LJ, Song L, et al. A phase II prospective study of definitive thoracic concurrent chemoradiation followed by consolidation chemotherapy for oligometastatic non-small cell lung cancer. J Clin Oncol. 2015;33. Suppl; Abstract e19008.
   Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014;12(12):1738–1761.
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27–39.
   PubMed Web of Science ®Google Scholar
• Lewis SL, Porceddu S, Nakamura N, et al. Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists. Am J Clin Oncol. 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Solanki AA, Weichselbaum RR, Appelbaum D, et al. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012;7:216.
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010;33(2):157–163.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101(8):560–570.
   PubMed Web of Science ®Google Scholar
• Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–2970.
   PubMed Web of Science ®Google Scholar
• Uppal A, Ferguson MK, Posner MC, et al. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014;31(6):735–748.
   PubMed Web of Science ®Google Scholar
• Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650.
   PubMed Web of Science ®Google Scholar